Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
161 hedge funds and large institutions have $2.65B invested in Akero Therapeutics in 2022 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 69 increasing their positions, 40 reducing their positions, and 19 closing their positions.
95% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 19
73% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 40
67% more capital invested
Capital invested by funds: $1.59B → $2.65B (+$1.06B)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
10% more funds holding
Funds holding: 146 → 161 (+15)
2.74% more ownership
Funds ownership: 100.67% → 103.41% (+2.7%)
2% less call options, than puts
Call options by funds: $54.4M | Put options by funds: $55.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$83.7M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$44.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$40.2M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$32.2M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$30.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$82.8M |
| 2 |
ST
Skorpios Trust
Limassol,
Cyprus
|
-$70.1M |
| 3 |
Janus Henderson Group
London,
|
-$40.1M |
| 4 |
YCM
Yiheng Capital Management
San Francisco,
California
|
-$27M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$26.9M |
AKRO Hedge Fund Activity: Q4 2022 in Review
161 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q4 2022, worth a combined $2.65B — up 67% from $1.59B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new AKRO positions and 19 closed out — a net gain of 18 holders — while 69 added to existing stakes and 40 trimmed.
The largest buyer was State Street, adding an estimated $83.7M. The largest seller was Goldman Sachs, cutting an estimated $82.8M.
- 161 institutional investors held Akero Therapeutics (AKRO) as of Q4 2022, up from 146 in Q3 2022.
- Funds reported $2.65B of Akero Therapeutics stock for Q4 2022, up 67% quarter-over-quarter.
- 37 funds opened new Akero Therapeutics positions in Q4 2022 and 19 closed out, a net change of +18 holders.
- The largest Akero Therapeutics buyer in Q4 2022 was State Street, an estimated $83.7M added.
- The largest Akero Therapeutics seller in Q4 2022 was Goldman Sachs, an estimated $82.8M sold.
Based on aggregated 13F filings for Q4 2022.